Bioventus Inc. (NASDAQ:BVS) shares traded -6.36% lower at $2.06 on Wall Street last session.
In accordance with the data, 3 analysts cover Bioventus Inc. (NASDAQ:BVS). The consensus rating among analysts is ‘Underweight’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $3.00, we find $6.50. Given the previous closing price of $2.20, this indicates a potential upside of 195.45 percent. BVS stock price is now -16.57% away from the 50-day moving average and -70.63% away from the 200-day moving average. The market capitalization of the company currently stands at $158.02M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
It has been rated a hold by 2 analysts and a buy by 0. Brokers who have rated the stock have averaged $6.50 as their price target over the next twelve months.
, while ‘Canaccord Genuity’ rates the stock as ‘Hold’.
In other news, D’Adamio Anthony, SVP & General Counsel sold 16,016 shares of the company’s stock on Apr 04. The stock was sold for $179,238 at an average price of $11.19. Upon completion of the transaction, the SVP & General Counsel now directly owns 40,132 shares in the company, valued at $82671.92. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 04, Chief Commercial Officer Nosenzo John sold 65,963 shares of the business’s stock. A total of $733,502 was realized by selling the stock at an average price of $11.12. This leaves the insider owning 83,932 shares of the company worth $0.17 million. Insiders disposed of 118,531 shares of company stock worth roughly $0.24 million over the past 1 year. A total of 15.64% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BVS stock. A new stake in Bioventus Inc. shares was purchased by NANTAHALA CAPITAL MANAGEMENT, LLC during the first quarter worth $780,000. INDEXIQ ADVISORS LLC invested $61,000 in shares of BVS during the first quarter. In the first quarter, STATE OF WISCONSIN INVESTMENT BOARD acquired a new stake in Bioventus Inc. valued at approximately $61,000. CWM, LLC acquired a new stake in BVS for approximately $40,000. MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. purchased a new stake in BVS valued at around $28,000 in the second quarter. In total, there are 153 active investors with 68.50% ownership of the company’s stock.
Bioventus Inc. (NASDAQ: BVS) opened at $2.1600 on Tuesday. During the past 12 months, Bioventus Inc. has had a low of $1.65 and a high of $15.10. As of last week, the company has a debt-to-equity ratio of 1.24, a current ratio of 0.90, and a quick ratio of 0.70. The fifty day moving average price for BVS is $2.4692 and a two-hundred day moving average price translates $7.0146 for the stock.
The latest earnings results from Bioventus Inc. (NASDAQ: BVS) was released for Jul, 2022. According to the Medical Devices Company, earnings per share came in at $0.1, missing analysts’ expectations of $0.16 by -0.06. This compares to -$0.05 EPS in the same period last year. The net profit margin was -24.60% and return on equity was -29.90% for BVS. The company reported revenue of $128.66 million for the quarter, compared to $108.89 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 18.16 percent. For the current quarter, analysts expect BVS to generate $141.59M in revenue.
Bioventus Inc.(BVS) Company Profile
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company’s restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician’s office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
